Targets › PRNP
1 program from 1 company in 1 trial: 1 Phase 1; Psychiatry; next expected readout Aug 2029.
Its primary physiological function is unclear. May play a role in neuronal development and synaptic plasticity. (UniProt, P04156)
Open in Phaseline: the race on PRNP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Broad Institute of MIT and Harvard | PrP-siRNA (2439-s4, 2439-exNA) Divalent siRNA targeting PRNP mRNA | PRNP | Phase 1 | Prion Disease | Aug 2029 |
Prion Disease (1)
other (1)
Broad Institute of MIT and Harvard (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.